165 related articles for article (PubMed ID: 37732324)
1. A novel marker integrating multiple genetic alterations better predicts platinum sensitivity in ovarian cancer than HRD score.
Yang F; Wei W; Li G; Lan Q; Liu X; Gao L; Zhang C; Fan J; Li J
Front Genet; 2023; 14():1240068. PubMed ID: 37732324
[No Abstract] [Full Text] [Related]
2. A Functional Homologous Recombination Assay Predicts Primary Chemotherapy Response and Long-Term Survival in Ovarian Cancer Patients.
Tumiati M; Hietanen S; Hynninen J; Pietilä E; Färkkilä A; Kaipio K; Roering P; Huhtinen K; Alkodsi A; Li Y; Lehtonen R; Erkan EP; Tuominen MM; Lehti K; Hautaniemi SK; Vähärautio A; Grénman S; Carpén O; Kauppi L
Clin Cancer Res; 2018 Sep; 24(18):4482-4493. PubMed ID: 29858219
[No Abstract] [Full Text] [Related]
3. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
4. Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.
Sztupinszki Z; Diossy M; Borcsok J; Prosz A; Cornelius N; Kjeldsen MK; Mirza MR; Szallasi Z
Clin Cancer Res; 2021 Oct; 27(20):5681-5687. PubMed ID: 34380641
[TBL] [Abstract][Full Text] [Related]
5. Homologous recombination deficiency in diverse cancer types and its correlation with platinum chemotherapy efficiency in ovarian cancer.
Wen H; Feng Z; Ma Y; Liu R; Ou Q; Guo Q; Shen Y; Wu X; Shao Y; Bao H; Wu X
BMC Cancer; 2022 May; 22(1):550. PubMed ID: 35578198
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract][Full Text] [Related]
7. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
8. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
9. Potential value of the homologous recombination deficiency signature we developed in the prognosis and drug sensitivity of gastric cancer.
Wu X; Wang Q; Liu P; Sun L; Wang Y
Front Genet; 2022; 13():1026871. PubMed ID: 36468004
[No Abstract] [Full Text] [Related]
10. The Great Majority of Homologous Recombination Repair-Deficient Tumors Are Accounted for by Established Causes.
Štancl P; Hamel N; Sigel KM; Foulkes WD; Karlić R; Polak P
Front Genet; 2022; 13():852159. PubMed ID: 35783256
[No Abstract] [Full Text] [Related]
11. Genomic profiling in ovarian cancer retreated with platinum based chemotherapy presented homologous recombination deficiency and copy number imbalances of CCNE1 and RB1 genes.
da Costa AABA; do Canto LM; Larsen SJ; Ribeiro ARG; Stecca CE; Petersen AH; Aagaard MM; de Brot L; Baumbach J; Baiocchi G; Achatz MI; Rogatto SR
BMC Cancer; 2019 May; 19(1):422. PubMed ID: 31060523
[TBL] [Abstract][Full Text] [Related]
12. Clinical assays for assessment of homologous recombination DNA repair deficiency.
Stover EH; Fuh K; Konstantinopoulos PA; Matulonis UA; Liu JF
Gynecol Oncol; 2020 Dec; 159(3):887-898. PubMed ID: 33012552
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.
Galland L; Ballot E; Mananet H; Boidot R; Lecuelle J; Albuisson J; Arnould L; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Bergeron A; Derangère V; Ghiringhelli F; Truntzer C; Ladoire S
NPJ Breast Cancer; 2022 Mar; 8(1):28. PubMed ID: 35246547
[TBL] [Abstract][Full Text] [Related]
14. Dynamically Accumulating Homologous Recombination Deficiency Score Served as an Important Prognosis Factor in High-Grade Serous Ovarian Cancer.
Su R; Liu Y; Wu X; Xiang J; Xi X
Front Mol Biosci; 2021; 8():762741. PubMed ID: 34869593
[No Abstract] [Full Text] [Related]
15. Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients.
Li Y; Zhang X; Gao Y; Shang C; Yu B; Wang T; Su J; Huang C; Wu Y; Guo H; Ha C
Front Oncol; 2020; 10():625866. PubMed ID: 33747898
[TBL] [Abstract][Full Text] [Related]
16. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
18. Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
Li Y; Nie Y; Guo H; Guo H; Ha C; Li Y
Front Oncol; 2022; 12():847085. PubMed ID: 35372049
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma.
Takaya H; Nakai H; Takamatsu S; Mandai M; Matsumura N
Sci Rep; 2020 Feb; 10(1):2757. PubMed ID: 32066851
[TBL] [Abstract][Full Text] [Related]
20. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
